Home / Compounds / Thymosin alpha-1

Thymosin alpha-1

Immunomodulatory peptide · Zadaxin in countries where it is licensed. Also written Ta1

UK status

Not licensed in the UK

Availability

Licensed in some countries

Evidence base

Human RCT for its licensed indications

Controlled drug

No

Thymosin alpha-1 sits in an awkward regulatory gap. Dozens of countries license it. The MHRA and FDA never have. Both of those facts are worth taking seriously, and neither supports what it is sold for online.

01What it is

The thymus is the gland where T cells, the immune system's targeting cells, are trained. It produces a range of signalling peptides, and thymosin alpha-1 is a synthetic version of one of them, 28 amino acids long, derived from a larger precursor protein.

Rather than suppressing or stimulating the immune system wholesale, it is described as modulating it: shifting the balance of immune responses. That is why it has been studied as an adjunct to other treatments rather than as a treatment on its own.

02How it came about

Thymosin alpha-1 was characterised in the 1970s in work on thymic peptides. It was developed as Zadaxin and licensed across a large number of countries, principally as an adjunct in chronic hepatitis B and C, with some jurisdictions also approving it in certain cancers and as a vaccine adjuvant.

It attracted renewed attention during the covid pandemic, when it was studied in severe infection, and subsequently in long covid, which is a substantial part of why it is now sold online.

03UK legal and licensing status

The gap is worth thinking about honestly rather than assuming either side is simply right. Many of its licences are in jurisdictions where the hepatitis burden is much higher and the trial evidence was generated locally. The MHRA and FDA have not been presented with, or have not accepted, a package meeting their requirements. Neither of those is the same as the compound being useless or being suppressed.

04How it works

The described mechanism is modulation of T cell function and maturation, with effects on the balance between different immune response types, and on the activity of natural killer cells and dendritic cells. In its licensed hepatitis use, the aim is to help the immune system respond to the virus alongside antiviral treatment.

05What it is not

Claims that attach themselves to this compound and do not hold up.

• Not licensed in the UK or the US. Widely licensed elsewhere, which does not transfer.
• Not a general immune booster. Its licensed uses are specific and adjunctive. Immune boosting is a marketing concept, not a clinical one, and a modulator is not a booster.
• Not an established long covid treatment. It has been studied. Studied is not the same as shown to work, and long covid trial evidence in general remains thin.
• Not the same as TB-500. Different thymosin, different family, different everything. The shared word causes a lot of confusion.

06What the evidence shows

There is genuine randomised trial evidence supporting its licensed uses in chronic hepatitis, which is why multiple regulators approved it. There is a further literature in sepsis and severe infection, including covid, with mixed results.

07Reported harms

In licensed use the safety profile is described as favourable, with injection site reactions the most common issue. That is a meaningful statement because it comes from regulated use in real patients over years, unlike most compounds in this register.

Caveats still apply. Anyone with an autoimmune condition, or taking immunosuppressants after a transplant, is contemplating something that acts on the immune system with no UK guidance and no prescriber able to advise on it. Grey-market product carries the usual problems.

08Interactions and cautions

The important ones are conceptual rather than documented: immunosuppressant therapy, and autoimmune disease, where modulating immune activity is precisely the thing you may not want. No UK SPC exists to consult.

09Stopping

Not well documented outside its licensed courses, which are time-limited by protocol rather than open-ended.

10Monitoring

In licensed hepatitis use, viral load, liver function and immune markers, under specialist care. Bought online, nothing is monitored.

11Questions worth asking

Take these to a doctor or pharmacist. A good clinician will not mind being asked, and the answers are specific to you in a way nothing on this page can be.

1. Do I have a condition this is actually licensed for anywhere?
2. Do I have an autoimmune condition, or take anything that suppresses my immune system?
3. If this is for long covid, is there an NHS service or trial I should be in instead?

12Common questions

13Sources

Links go to the authoritative source. Where a document sits behind a paywall or moves around, the full citation is given so you can find it yourself.

1. Thymosin alpha-1 in chronic hepatitis, trial literaturePubMed
2. Thymosin alpha-1 in sepsis and covidPubMed
3. TB-500 record/compounds/tb-500/
4. Unlicensed medicines guidanceMHRA